KRAS and colorectal carcinoma: Accordingly, treatment of KRAS (HCT116) and BRAF (HT-29)-mutated human CRC cells with the ERK1/2 inhibitor, SCH7729846, reduced LRP6 phosphorylation on serine 1490, a residue required for Wnt signal transduction.